Ensysce Financial Statements From 2010 to 2025

ENSC Stock  USD 3.88  0.02  0.51%   
Ensysce Biosciences financial statements provide useful quarterly and yearly information to potential Ensysce Biosciences investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Ensysce Biosciences financial statements helps investors assess Ensysce Biosciences' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Ensysce Biosciences' valuation are summarized below:
Gross Profit
-1.2 M
Profit Margin
(1.79)
Market Capitalization
5.5 M
Revenue
4.4 M
Earnings Share
(11.45)
We have found one hundred twenty available fundamental signals for Ensysce Biosciences, which can be analyzed and compared to other ratios and to its rivals. Investors should ensure to verify all of Ensysce Biosciences' prevailing performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road.

Ensysce Biosciences Total Revenue

2.23 Million

Check Ensysce Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ensysce Biosciences' main balance sheet or income statement drivers, such as Tax Provision of 373.2 K, Interest Income of 93.6 K or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 17.63, Dividend Yield of 22.28 or PTB Ratio of 0.0. Ensysce financial statements analysis is a perfect complement when working with Ensysce Biosciences Valuation or Volatility modules.
  
Check out the analysis of Ensysce Biosciences Correlation against competitors.
For information on how to trade Ensysce Stock refer to our How to Trade Ensysce Stock guide.

Ensysce Biosciences Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets5.3 M5.6 M127.4 M
Slightly volatile
Total Current Liabilities2.3 T2.2 T282.8 B
Slightly volatile
Cash3.4 M3.5 M2.7 M
Pretty Stable
Cash And Short Term Investments3.7 T3.5 T448.8 B
Slightly volatile
Common Stock Shares Outstanding732.6 M697.7 M102.4 M
Slightly volatile
Short Term Investments4.2 TT1.2 T
Slightly volatile
Liabilities And Stockholders Equity5.3 M5.6 M127.4 M
Slightly volatile
Capital Surpluse129.5 M123.3 M41.8 M
Slightly volatile
Total Liabilities10.6 B10.1 B1.3 B
Slightly volatile
Total Current Assets5.6 T5.3 T684.9 B
Slightly volatile
Common Stock129136118.5 M
Slightly volatile
Other Current LiabilitiesT1.9 T244.1 B
Slightly volatile
Warrants149.4 M163.1 M184.4 M
Slightly volatile
Accounts Payable1.5 M1.4 M887.3 K
Slightly volatile
Non Current Assets Total239.9 K252.6 K126.5 M
Slightly volatile
Net Receivables171.2 K124.1 K203.8 K
Pretty Stable
Common Stock Total Equity63.9 K60.9 K21.4 K
Slightly volatile
Non Current Liabilities Total9.6 K10.1 K5.4 M
Slightly volatile
Other Current Assets1.8 T1.7 T220.2 B
Slightly volatile
Deferred Long Term Liabilities1.4 K1.6 K1.7 K
Slightly volatile
Non Current Liabilities Other298.6 K314.3 K5.3 M
Slightly volatile
Short and Long Term Debt Total316.7 B301.7 B38.7 B
Slightly volatile
Long Term Debt153.1 K161.2 K718.1 K
Very volatile
Short and Long Term Debt286.6 K301.7 K4.1 M
Pretty Stable
Capital Stock1291361.3 K
Slightly volatile
Other Liabilities2.9 M3.3 M3.6 M
Slightly volatile
Cash And Equivalents2.7 M2.8 M9.9 M
Slightly volatile

Ensysce Biosciences Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Tax Provision373.2 K281.2 K173.2 K
Slightly volatile
Interest Income93.6 K98.6 K675.7 K
Pretty Stable
Other Operating Expenses11.5 M14.9 M6.1 M
Slightly volatile
Cost Of Revenue6.2 M8.7 M3.8 M
Slightly volatile
Non Operating Income Net Other5.1 M6.8 M4.5 M
Slightly volatile
Selling General AdministrativeT4.7 T604.8 B
Slightly volatile
Selling And Marketing Expenses2.9 M3.2 M3.5 M
Slightly volatile
Research Development7.6 T7.2 T925 B
Slightly volatile

Ensysce Biosciences Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow3.7 T3.5 T448.7 B
Slightly volatile
Begin Period Cash Flow1.2 T1.1 T144 B
Slightly volatile
Stock Based Compensation116.3 B110.7 B14.2 B
Slightly volatile
Issuance Of Capital Stock1.6 M1.7 MM
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio17.6318.5681 K
Slightly volatile
Dividend Yield22.2823.46428
Slightly volatile
Days Sales Outstanding17.4418.3639.9815
Slightly volatile
Average Payables1.3 M1.5 M1.6 M
Slightly volatile
Stock Based Compensation To Revenue0.430.452.2496
Slightly volatile
EV To Sales17.518.4281 K
Slightly volatile
Payables Turnover2.823.534.9597
Slightly volatile
Sales General And Administrative To Revenue3.222.763.5
Slightly volatile
Research And Ddevelopement To Revenue2.53.062.4097
Slightly volatile
Capex To Revenue0.00.00.0
Slightly volatile
Cash Per Share2.1 MM256.9 K
Slightly volatile
Days Payables Outstanding10210745.6 K
Pretty Stable
Income Quality0.890.93946.6983
Slightly volatile
Current Ratio3.332.42158.1839
Slightly volatile
Receivables Turnover10.6620.589.9468
Slightly volatile
Capex Per Share0.00.00.0
Slightly volatile
Average Receivables104.4 K198.8 K127.5 K
Slightly volatile
Revenue Per Share1.081.137.6236
Slightly volatile
Debt To Assets56.6 K53.9 K6.9 K
Slightly volatile
Graham Number10.3311.6212.6688
Slightly volatile
Days Of Payables Outstanding10210745.6 K
Pretty Stable
Quick Ratio3.342.42158.188
Slightly volatile
Cash Ratio0.00.07.0394
Slightly volatile
Days Of Sales Outstanding17.4418.3639.9815
Slightly volatile
Fixed Asset Turnover1011074.8 K
Pretty Stable
Debt Ratio56.6 K53.9 K6.9 K
Slightly volatile
Price Sales Ratio17.6318.5681 K
Slightly volatile
Asset Turnover0.90.950.9114
Pretty Stable

Ensysce Biosciences Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap15.5 M16.3 MB
Slightly volatile
Enterprise Value285.1 B271.5 B93.4 B
Slightly volatile

Ensysce Fundamental Market Drivers

Cash And Short Term Investments3.5 T

Ensysce Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Ensysce Biosciences Financial Statements

Ensysce Biosciences stakeholders use historical fundamental indicators, such as Ensysce Biosciences' revenue or net income, to determine how well the company is positioned to perform in the future. Although Ensysce Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Ensysce Biosciences' assets and liabilities are reflected in the revenues and expenses on Ensysce Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Ensysce Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue182.9 K192 K
Cost Of Revenue8.7 M6.2 M
Stock Based Compensation To Revenue 0.45  0.43 
Sales General And Administrative To Revenue 2.76  3.22 
Research And Ddevelopement To Revenue 3.06  2.50 
Revenue Per Share 1.13  1.08 
Ebit Per Revenue(5.53)(5.80)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Ensysce Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ensysce Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ensysce Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ensysce Biosciences Stock:
Check out the analysis of Ensysce Biosciences Correlation against competitors.
For information on how to trade Ensysce Stock refer to our How to Trade Ensysce Stock guide.
You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ensysce Biosciences. If investors know Ensysce will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ensysce Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(11.45)
Revenue Per Share
10.216
Quarterly Revenue Growth
6.853
Return On Assets
(0.63)
Return On Equity
(2.05)
The market value of Ensysce Biosciences is measured differently than its book value, which is the value of Ensysce that is recorded on the company's balance sheet. Investors also form their own opinion of Ensysce Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Ensysce Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ensysce Biosciences' market value can be influenced by many factors that don't directly affect Ensysce Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ensysce Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ensysce Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ensysce Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.